Eagle Pharmaceuticals Reports Third Quarter 2022 Results
07.11.2022 - Q3 2022 net loss was $(0.27) per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share1Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021Nine-month 2022 net income was ...
Source: wallstreet-online.de